Trevena (TRVN) Announces Earnings Results, Misses Expectations By $0.04 EPS

Trevena (NASDAQ:TRVN) posted its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.04), MarketWatch Earnings reports. The company had revenue of $0.23 million during the quarter, compared to the consensus estimate of $3.00 million.

Shares of Trevena stock opened at $1.46 on Friday. Trevena has a 12 month low of $0.38 and a 12 month high of $3.58. The company has a market cap of $121.01 million, a P/E ratio of -1.21 and a beta of 2.61. The company has a debt-to-equity ratio of 0.16, a current ratio of 4.30 and a quick ratio of 4.30.

A number of brokerages have commented on TRVN. Zacks Investment Research cut Trevena from a “buy” rating to a “hold” rating in a research report on Thursday, December 13th. HC Wainwright restated a “hold” rating and issued a $1.25 price target on shares of Trevena in a research report on Thursday. Four analysts have rated the stock with a hold rating and four have given a buy rating to the company. Trevena has an average rating of “Buy” and a consensus target price of $5.63.

In related news, CEO Maxine Gowen acquired 50,000 shares of the stock in a transaction dated Friday, February 1st. The stock was acquired at an average cost of $1.02 per share, with a total value of $51,000.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Leon O. Moulder, Jr. acquired 100,000 shares of the stock in a transaction dated Friday, February 1st. The stock was bought at an average cost of $1.02 per share, with a total value of $102,000.00. The disclosure for this purchase can be found here. 4.60% of the stock is currently owned by corporate insiders.

Several large investors have recently bought and sold shares of the company. Vanguard Group Inc lifted its stake in shares of Trevena by 29.2% in the 3rd quarter. Vanguard Group Inc now owns 2,618,634 shares of the biopharmaceutical company’s stock valued at $5,552,000 after purchasing an additional 592,152 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Trevena by 29.2% in the 3rd quarter. Vanguard Group Inc. now owns 2,618,634 shares of the biopharmaceutical company’s stock valued at $5,552,000 after purchasing an additional 592,152 shares during the last quarter. BlackRock Inc. lifted its stake in shares of Trevena by 151.4% in the 3rd quarter. BlackRock Inc. now owns 1,873,311 shares of the biopharmaceutical company’s stock valued at $3,971,000 after purchasing an additional 1,128,041 shares during the last quarter. Renaissance Technologies LLC lifted its stake in shares of Trevena by 67.2% in the 3rd quarter. Renaissance Technologies LLC now owns 872,300 shares of the biopharmaceutical company’s stock valued at $1,849,000 after purchasing an additional 350,600 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in shares of Trevena by 17.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 541,099 shares of the biopharmaceutical company’s stock valued at $1,147,000 after purchasing an additional 80,437 shares during the last quarter. 24.22% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Trevena (TRVN) Announces Earnings Results, Misses Expectations By $0.04 EPS” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another site, it was copied illegally and republished in violation of US and international copyright & trademark laws. The correct version of this article can be read at https://www.dispatchtribunal.com/2019/03/15/trevena-trvn-announces-earnings-results-misses-expectations-by-0-04-eps.html.

About Trevena

Trevena, Inc, a biopharmaceutical company, develops therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. Its product candidates include OLINVO injection, a G protein biased ligand of the µ opioid receptor that has completed Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is preferred; TRV250, a G protein biased ligand targeting the d-receptor, which is in Phase I clinical study for the treatment of migraine; and TRV734, a small molecule G protein biased ligand of the µ opioid receptor that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain, as well as TRV027 for the treatment of acute heart failure.

Further Reading: Short Selling

Earnings History for Trevena (NASDAQ:TRVN)

Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.